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Emerging infectious diseases (EID) are currently the major threat to public health worldwide and
most EID events have involved zoonotic infectious agents. Central Africa in general and Gabon in
particular are privileged areas for the emergence of zoonotic EIDs. Indeed, human incursions
in Gabonese forests for exploitation purposes lead to intensified contacts between humans
and wildlife thus generating an increased risk of emergence of zoonotic diseases. In Gabon,
51 endemic or potential endemic viral infectious diseases have been reported. Among them,
22 are of zoonotic origin and involve 12 families of viruses. The most notorious are dengue,
yellow fever, ebola, marburg, Rift Valley fever and chikungunya viruses. Potential EID due to
wildlife in Gabon are thereby plentiful and need to be inventoried. The Gabonese Public Health
system covers geographically most of the country allowing a good access to sanitary information
and efficient monitoring of emerging diseases. However, access to treatment and prevention is
better in urban areas where medical structures are more developed and financial means are
concentrated even though the population is equally distributed between urban and rural areas.
In spite of this, Gabon could be a good field for investigating the emergence or re-emergence of
zoonotic EID. Indeed Gabonese health research structures such as CIRMF, advantageously
located, offer high quality researchers and facilities that study pathogens and wildlife ecology,
aiming toward a better understanding of the contact and transmission mechanisms of new
pathogens from wildlife to human, the emergence of zoonotic EID and the breaking of species
barriers by pathogens.
Introduction
Despite intensive research and considerable effort from
public health agencies to prevent or eradicate infectious
diseases, emerging infectious diseases (EID) are currently
the major threat to public health worldwide.1 Indeed, many
new infectious agents, characterized by a high pathogenic
potential, have been recently identified. Furthermore, some
well known pathogens have been expanding their territories,
causing increasing concerns in the recent decades due
to changing epidemiological patterns.2 Most of these
EID events have involved zoonotic infectious agents: more
than 60% of EID affecting humans have a zoonotic origin3,4
and B75% of the diseases that have emerged over the past
two decades have wildlife sources.5 Therefore, zoonotic EID
represent a major and increasing threat to global health.1,3,6
Zoonoses refer to infectious diseases that are susceptible to
be transmitted from animals to humans and are responsible
worldwide for a great deal of pain, morbidity and even
human fatalities. Two categories of zoonotic diseases have
been described:4 (1) diseases for which transmission events
to humans are rare but once occurred, horizontal transmis-
sion from human-to-human maintains a more or less
sustainable infectious cycle (for example: ebola virus, from
naturally infected chiropteran to human epidemics); (2)
diseases for which direct or vector-mediated animal-to-
human transmission remains the common source of human
infection (for example: Rift Valley fever virus (RVFV),
mosquito-transmitted from infected domestic ungulates).
Emerging and re-emerging zoonoses include recently
identified infectious diseases, diseases that have recently
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evolved from a subclinical state to a clinical syndrome, and
previously known diseases that have recently displayed an
increase in incidence or that have spread to new regions,
hosts or vectors.4 However, a disease may not be recognized
as zoonotic at the first outset. The disease can spread
undetected for a period of time depending on the incubation
period (weeks to years), the epidemiological pattern of a
subclinical disease to a clinical picture (the emergence of the
symptoms depending on host or pathogen factors) or, if the
number of cases, in both human and animal populations, is
too small and undetectable during the initial stages of
transmission to suspect a link between the two events.7
Zoonotic EID outbreaks result from a now classically
accepted phenomenon of concurrency of fundamentals
and territories of emergence. Fundamentals include factors
related to the host, the vector (if any), the pathogen, and
favorable environmental factors (climate) although terri-
tories at risk are the product of human activity and high-risk
behavior among the human population. For instance,
territories (that is: city, district) with an inefficient disease
detection system or a failure to control vectors and other
carriers of diseases as well as man-made environmental
changes (breakdown of the water system, deforestationy)
will force an increase in contact between the human
population and wildlife.2,8
Tropical forests form the ecosystem harboring the highest
species richness of all terrestrial ecosystems and shelter
almost 50% of the total global biodiversity.9,10 This includes
wildlife, flora, multi-cellular organisms as well as an
immense diversity of pathogens including bacteria, parasites
and viruses. Actually, there is a latitudinal spatial gradient of
pathogenic species richness increasing towards the Equa-
tor.11 After the Amazonian Basin, the Congo basin in Central
Africa has the world’s second largest contiguous block of
tropical rainforest, which encompasses many areas that
remain largely undisturbed, due in large part to low human
population densities and the remoteness of interior rain-
forests.12 As wildlife host species richness is a good predictor
for the emergence of zoonotic EIDs with a wildlife origin,3
Central Africa in general, and Gabon in particular are
privileged areas for the emergence of zoonotic EIDs.
The potentialities of emerging zoonotic diseases from
wild to domestic environments
Latest reviews on EID show that nearly 75% of zoonotic EID
have a wildlife origin.3,5,13–15 In fact, the number of EID
events caused by pathogens coming from wildlife has
increased during the past six decades.3 The majority of
pathogens recorded were of viral origin.16 Therefore viral
zoonoses of wildlife origin represent the most significant and
growing threat to global health among all EIDs.3,13
As anthropogenic activities have been identified as the
cause of a significant majority of outbreaks,16,17 it is essential
to fully understand the mechanisms driving contacts bet-
ween wildlife and the human population as well as species-
jumping infections to set up public health information
campaigns. On the contrary, efforts to conserve areas rich
in wildlife diversity (13 National Parks were created in 2002
in Gabon) by reducing anthropogenic activity may have an
added value in reducing the likelihood of future zoonotic
disease emergence in these areas.3 EIDs in free-living wild
animals can be classified into three major groups on the
basis of key epizootiological criteria:18 (i) EIDs associated
with ‘spill-over’ from domestic animals to wildlife popula-
tions living in proximity; (ii) EIDs related directly to
human intervention, via host or parasite translocations; and
(iii) EIDs with no overt human or domestic animal involve-
ment. These phenomena have two major biological implica-
tions: first, many wildlife species are reservoirs of pathogens
that threaten domestic animal and human health; second,
wildlife EIDs pose a substantial threat to the conservation of
global biodiversity, with for example the disappearance of
the most great ape populations in protected areas in Central
Africa after the 2002–2003 ebola virus outbreaks.19–22
Emerging zoonotic diseases in Gabon
In Gabon, rainforests cover B80% of the territory.23 These
forests are known for their rich biodiversity of animal
and plant species.23 The human population, estimated at
1.5 million,24 lives more in cities (54%) than in rural areas.25
Gabon’s economy has relied in the past mainly on petroleum
exports, forest exploitation, and mining activities. Forest
habitats are now exploited by logging and mining compa-
nies, tourism and hunting activities, which produce about
17,500 metric tons per year of game meat. Altogether these
human incursions in Gabonese forests for exploitation
purposes lead to intensified contacts between humans and
wildlife and generate a risk of emergence of zoonotic
diseases.26 This risk is not strictly restricted to the forest
but exists countrywide as the urban demand for bush-meat
in Gabon is important (45 kg/per/year27). Indeed, every
Gabonese city has traditional and local food markets where
fresh and smoked bush-meat coming from all around the
country are available. Potential EIDs due to wildlife in Gabon
are thereby plentiful and need to be inventoried.
Known emerging viral diseases in Gabon
At least 51 endemic or potential endemic viral infectious
diseases have been reported in Gabon28 (Table 1). Among
them, 22 are of zoonotic origin and involve 12 families of
viruses. The most represented are Flaviviridae (dengue virus,
yellow fever virus (YFV), zika fever virus), Poxviridae
(monkeypox virus (MPXV)), Filoviridae (ebola and marburg
Viruses), Arenaviridae (lassa fever virus), Bunyaviridae
(RVFV) and Togaviridae (chikungunya virus).
During the past two decades, several outbreaks of these
zoonotic viral diseases have been reported in Gabon. All of
them had a major impact on the public health:
 Zaı¨re ebola virus (ZEBOV): in Gabon, ZEBOV outbreaks
occurred in 1994, 1996, 1997 and 2001;29 primary human
cases were generally contaminated by direct contact with
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dead wild animals, such as great apes (chimpanzee and
gorilla), which are highly susceptible to the disease, and
therefore human outbreaks were often preceded by an
animal epizootic (great apes). Since the first recorded
outbreak in 1976, 20 human epidemics have occurred in
Central Africa29,30 with three recent outbreaks in RDC and
Uganda in 2007 and 2008.
 Chikungunya virus (CHIKV): CHIKV has recently
dispersed to new regions of the world including Gabon
where two outbreaks in 2006 and 2007 mainly hit the
capital, Libreville.31,32 A total of 17,618 human cases were
reported.33 The outbreaks appeared concomitantly with
the spread in peridomestic urban areas of Aedes albopictus,
the mosquito known as the main vector of the most recent
epidemics of CHIKV.34 CHIKV disease had reemerged in
2001–200335 in the Indian Ocean after a 20-year gap with
a new epidemiological pattern including A. albopictus as
the main vector of epidemics and an adapted virus strain
presenting an original mutation suspected to be respon-
sible for an increase of pathogenicity.36
 Dengue virus (DENV): a DENV outbreak occurred in Gabon
simultaneously with the CHIKV outbreak in 2007,33 and
concurrent infections of DENV and CHIKV have been
reported in towns affected by the two outbreaks.34 Dengue
fever and the severe form of the disease, dengue hemorrhagic
fever (DHF), are caused by the world’s most prevalent
mosquito-borne virus.37 DENV is carried by Aedes aegypti
mosquito, which is strongly affected by ecological and
human drivers, but also influenced by climate (temperature,
humidity and solar radiation).37 Although DENV was known
to circulate among mosquitoes within limited areas in
West Africa and East Africa, dengue fever first emerged among
the African population during the epidemic of Nigeria in
1964–1968,38 then in Senegal in 198039 and Burkina Faso and
Kenya in 1982.40,41 Since then epidemic manifestations were
recorded in East Africa (Mozambique, Sudan, Djibouti,
Somalia, Eritrea), in Senegal and more recently in Gabon.34,42
It seems that dengue fever is on the edge of emergence in
Africa with the potential appearance of the devastating DHF
that is yet to be observed on the continent.
 Yellow Fever Virus (YFV): Gabon is officially designated as
an infected country. A YFV outbreak occurred in 1994 in
Ogooue-Ivindo Province, North East of Gabon with 44
cases reported.43 More recently, in 2009, Cameroon
reported a laboratory-confirmed case of yellow fever
(YF).44 YF has become an important public health issue
because of its case-fatality rate of 50% and the estimated
200,000 cases and 30,000 deaths that occur each year
worldwide. Also, despite the efficiency of the YF vaccine
and its inclusion in the national vaccination program,
human populations situated in remote areas have a
limited access to the public health system.
Potential emerging zoonotic diseases in Gabon
Based on serological evidence, several pathogens identified
among wild or domestic animals, are suspected to infect the
human populations of Gabon and therefore represent a
potential threat to public health. Among them are the
follows:
 Foamy virus: simian foamy virus (SFV), a retrovirus in the
Spumaretrovirinae subfamily, is widely prevalent in wild-
caught and captive-born non human primates.45,46 Con-
tamination between non-human primates and humans
can occur via contact with infectious body fluids, through
biting,45,47 or when manipulating fresh bush-meat.48,49
However, the potential for SFV to become a human disease
and to spread among human populations after cross-
species transmission is not yet fully understood.50
 Human monkeypox: Human monkeypox, caused by the
MPXV, a member of the genus Orthopoxvirus, is clinically
almost identical to ordinary smallpox.51 Humans become
infected through direct contact with infected wild
animals. It seems that monkeys are also incidental hosts
as the reservoir species of MPXV remain unknown
(most likely one or several rodents living in secondary
forests of Central Africa).51 Epidemiological surveys
recorded 47 cases of human monkeypox (7 lethal) in
Central Africa (RDC, Gabon, Congo, CAR, Cameroun,
Ivory Cost, Liberia, Sierra Leone and Nigeria)52 with
possible secondary transmission in the human popula-
tion. Since 1980, the large majority of cases to be reported
from the DRC mainly concern children.51 In 72% of those
cases, an animal source of infection was suspected whereas
secondary transmission from human source was presumed
for the remaining cases. The longest documented chain of
infection did not exceed four generations of person-to
person transmission. There is only little probability of a
large epidemic spread of MXPV.53
 Rift valley fever virus (RVFV): Rift Valley fever is an African
disease that affects both livestock and humans. RVF
outbreaks are associated with persistent heavy rainfall,
sustained flooding and appearance of large numbers of
mosquitoes, the main vector. Localized heavy rainfall is
seldom sufficient to create conditions for an outbreak;54,55
Rift Valley fever is a good example of a disease that is well
coupled with climatic anomalies; and Gabon is one of the
African countries known to have some evidence of RVFV
circulation as antibodies of the disease has been found in
humans and livestock.55
Impact of a changing environment
Climatic variations and extreme weather events have a
profound impact on infectious diseases:56 for example, the
emergence of vector-borne diseases is highly sensitive to
changes in environmental conditions (rainfall, temperature,
severe weather events).56 Indeed arthropod vectors (that is
mosquito, ticksy) are devoid of thermostatic mechanisms,
hence reproduction and survival rates are strongly affected
by fluctuations in temperature.37 A rise in arthropod-
borne EID events due to climate anomalies has been
observed during the 1990’s.3 Average global temperatures
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are predicted to be 1.0–3.51C by 2100.57 Further epidemic
events of vector-borne diseases due to climate change are,
therefore, to be expected.
Concerning other zoonotic infectious diseases like ebola,
marburg or RVF, too little information is available concern-
ing their ecology to be able to assess the impact of climate
changes on the potential emergence or re-emergence of
these diseases. However some preliminary reports show a
strong association between wet environment (rainfall and
hydrographic conditions directly dependent on climate and
climate change) and the recent reemergence of ebola fever in
Gabon and RDC.58 Also El Nin˜o/Southern oscillation (ENSO)
is the strongest naturally occurring source of climate
variability around the globe,59 and more than 75% of RVF
outbreaks between 1950 and 1988 occurred during warm
ENSO event periods.54 Moreover, RVF epidemics between
1950 and 1998 have coincided with unusually high rainfall
in East Africa.60
Epidemic prevention and control
Existing structures in Gabon (data cited below was updated in
2007, ministry of public health, Gabon61)
Gabon has one of the highest expenditure on health per
capita in Africa. In 2006, Gabon’s total health care expenses
were comparable to eastern European countries and most
southern American countries:62 between 300 and 1000 US$
per capita.
The Gabonese Public Health System comprises five
different health sectors: (1) the civilian public sector under
the public Health and Hygiene Ministry, (2) the public
military sector under the Ministry of Defense, (3) the
National Health Social Security Funding and private insur-
ances, (4) the private health sector and (5) the traditional
health sector.61
This public Health system geographically covers most of
the country allowing a good access to sanitary information
and efficient monitoring of emerging diseases. However,
access to treatment and prevention is much better in urban
areas where medical structures are more developed, more
organized with higher level of technicality and material61
while the population is equally distributed between urban
and rural areas (Table 2). A total of 60% of human and
equipment resources from the Gabonese government are
allocated to the main cities. In fact, all hospitals and clinics
are found in Libreville, Port Gentil, Franceville and the
surrounding areas, whereas in the distant rural areas, the
numerous small health structures like Mother and Child
Health Centers, Health Medical Centers, and Primary Care
Health Center (Table 2) are often old with limited basic
equipment and drugs.61 Also the medical staff is more
concentrated in urban areas (Table 3). Indeed, more than
70% of the doctors and midwives are assigned to urban areas
as well as 58% of the druggists. Only public nurses are
equally distributed between rural and urban areas.
To fight against diseases, Gabon has developed 17 national
health control programs. These programs monitor diseases
such as HIV and sexually transmitted diseases, malaria,
tuberculosis and also include a wide vaccination program,
which covers 100% of the Gabonese territory. Despite the
existence of 10 epidemiological stations distributed around
the country in both rural and urban areas (Table 2) that act as
surveillance outposts, there is no other national health
program to combat the more neglected EIDs.
In addition to public health Ministry activities, there are
the following in Gabon:
 The CENAREST (National Center for Scientific and Tech-
nologic Research) that evaluates and carries out research in
Gabon, contributes to the application and promotion of
research results and supports research training.
 The CIRMF (International Medical Research Centre of
Franceville), a Gabonese world-renowned scientific
research center, inaugurated in 1979, the CIRMF had for
an initial focus to study the reasons for infertility in
Central African populations. By the mid 1980s, CIRMF
broadened its research to focus also on tropical diseases
including HIV, trypanosomiasis and malaria. More re-
cently CIRMF concentrated also on EIDs including the
deadly ebola and marburg viruses, CHIKV and DENV.63
Its central position in Africa and its world-renowned
researchers ensure that CIRMF benefits from support and
collaboration from several international institutions in-
cluding the WHO (World Health Organization), the
CIRAD (Centre de Coope´ration Internationale en Re-
cherche Agronomique pour le de´veloppement), the IRD
(Institut de Recherche pour le De´veloppement), the
Pasteur Institute, the CDC (Centers for Disease Control
and Prevention), and several overseas universities from
Europe, North America, South America and Asia.
 International NGOs (non-governmental organizations)
are also involved in research on emerging diseases in
Gabon. For example, the WCS (Wildlife Conservation
Society) with its ‘One World, One Health’ Program and
the Zoological Society of London and its ‘Mikongo
Conservation Centre’ are working on great ape diseases,
wildlife monitoring and the bush meat trade.
Regional organizations
In Central Africa there are few regional organizations
involved in public health:
 The OCEAC (Organisation de coordination pour la lute
contre les ende´mies en Afrique Centrale) is an organiza-
tion of coordination and cooperation to fight major
endemic diseases in Central Africa. Created in 1963, in
Yaounde, by the determination of the health ministers of
Cameroon, Congo, Gabon, CAR and Chad, it was
originally known as the OCCGEAC until 1965. The
Equatorial Guinea joined later the OCEAC. Its goals are
to (1) coordinate public health policies and actions in
Central African region, (2) participate in the training of
the medical staff of member countries of the organization,
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(3) coordinate applied research projects undertaken by
national institutions, (4) implement missions of expertise
in the different areas of health sciences, (5) contribute to
the public health promotion in the member countries and
(6) support the actions undertaken in response to health
emergencies. Today OCEAC is in charge of regional health
programs and projects like the Sub Regional Program
against HIV/AIDS, the Harmonization Program for Phar-
maceutical Policy, the Regional Program to fight human
African trypanosomiasis and research projects on malaria.
 The CEMAC (Communaute´ E´conomique des E´tats
d’Afrique CentraleFEconomic Community of Central
African States) is an economic community of the African
Union for promotion of regional economic co-operation
in Central Africa. Member countries include Gabon,
Republic of Congo, Equatorial Guinea, CAR, Cameroon
and Chad. It ‘aims to achieve collective autonomy, raise
the standard of living of its populations and maintain
economic stability through harmonious cooperation’. It
was established in 1983 and its ultimate goal is to establish
a Central African Common Market. However CEMAC may
have a role in the public health systems in Central Africa:
in 2009, CEMAC signed a memorandum of understanding
with Germany, which donated a 23 million euro grant for
the prevention of HIV in Central Africa.
 The CIESPAC (Centre inter-e´tats d’Enseignement en Sante´
Publique pour l’Afrique centrale) is a sub-regional public
health training institution, originally located in Brazza-
ville. It was created to provide Central African countries
with qualified health service staff and managers. It offers
several courses, the most recent of which is recognized
with a professional diploma in public health and targets
mainly potential health district managers.64 The civil war
events that occurred in Brazzaville in the late nineties
provoked the transfer of the institution to Yaounde´,
Cameroon.
 The CAMES (Conseil Africain et Malgache pour
l’Enseignement Supe´rieurFAfrican and Malagasy Council
for Higher Education) exists to (1) promote and encourage
the understanding and the solidarity between member
States, (2) establish a permanent cultural and scientific
cooperation between member states, (3) collect and
diffuse all academic and research documents, (4) prepare
agreement drafts between states concerned by Higher
Education and Research and contribute to their imple-
mentation and finally (5) develop and promote dialogues
to coordinate the higher education system and research so
as to standardize programs and recruitment levels. This
means that Gabonese university lecturers and researchers
(in particular health researcher) are assessed by CAMES
before obtaining a promotion.
International organizations
Gabon is part of the Global Outbreak Alert and Response
Network (GOARN), which contributes towards global
health security by,65 (1) fighting the international spread ofTa
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outbreaks, (2) ensuring that appropriate technical assistance
rapidly reaches affected countries, and (3) contributing to
long-term epidemic preparedness and capacity building. On
top of that, the CDC, in conjunction with the WHO, has
developed practical, hospital-based guidelines, titled Infec-
tion Control for Viral Haemorrhagic Fevers in the African
Health Care Setting. This manual helps health-care facilities
to recognize cases and prevent further hospital-based disease
transmission using locally available materials and only little
financial resources (http://www.cdc.gov/ncidod/dvrd/spb/
mnpages/dispages/vhf.htm). Moreover, in November 2007,
a meeting to discuss the integrated control of neglected
zoonotic diseases in Africa was held in Nairobi, Kenya. It was
organized by the WHO and jointly supported by the
European Commission, the ILRI (International Livestock
Research Institute), the Danish Centre for Health Research
and Development (formerly the Danish Bilharziasis Labora-
tory), the FAO (United Nations Food and Agriculture
Organization), the OIE (World Organisation for Animal
Health) and the African Union.66
Conclusion
Infectious diseases, including zoonoses, remain the major
and increasing health threat in most developing coun-
tries.1,3,6,67 Even if in industrialized countries, cardiovascular
diseases and cancers are considered to be the main causes of
illness and death, special attention still needs to be paid to
zoonotic EID.67 This statement is now well described by the
‘one healthFone medicine-one world’ concept which is a
worldwide strategy for expanding interdisciplinary colla-
boration and communications in all aspects of health care
for humans and animals and the interaction with environ-
mental factors. Also, viral hemorrhagic fevers, because of
their high infectiousity and the dramatic outcome, have
attracted the attention of the medical world and the public
in Africa and around the world to this particular category of
EID.68
However, global effort in EID surveillance and investiga-
tion is inadequately allocated. Indeed, the majority of
scientific resources focus on places from where the next
important emerging pathogen is least likely to originate.3
Jones et al. advocated for the re-allocation of resources to EID
hotspots in lower latitudes, such as tropical Africa because of
the critical need for health monitoring and identification of
new potentially zoonotic pathogens in African wildlife
populations, and this to be used as a forecast measure for
EIDs.3,48,67
Like other African countries, Gabonese resources for public
health and health monitoring are unequally allocated; 60 %
are spent at a central level. Public health services and clinical
practitioners need more resources to be able to actively
educate the public about the risks of repeated contacts with
wildlife or other sources potentially harmful for health.48
However, Gabon could be considered as a good model to
investigate the emergence or re-emergence of zoonotic EID.
On one hand, Gabonese forests are a hot spot for biodiversity
(wild animals and unknown pathogens) and on the other
hand there is a relatively small population (1.5 million of
habitants), which is often in contact with surrounding
wildlife. Also, the CIRMF, a research center advantageously
located, offers high quality researchers and facilities that
study pathogens and wildlife ecology. Altogether the
combination of these factors should help to better under-
stand the mechanisms of contact and transmission of new
pathogens from wildlife to human, the emergence of
zoonotic EID and the breaking of species barriers by the
pathogens. Indeed the emergence of infectious diseases in
wildlife is a continuous and ongoing process. The factors
that give rise to zoonotic EID, such as ecosystem perturba-
tions and modifications, climate changes, migrations of
reservoirs species, pathogens or vectors, and intrinsic
changes of pathogens may be of natural origin or due to
human influences.17 To understand the underlying mechan-
isms that govern relationships between reservoir species,
ecological factors and environmental perturbations with the
emergence, transmission and dissemination of viral diseases
in tropical forests, the CIRMF wishes to set up permanent
surveillance of the health of the population by the establish-
ment of (1) a network reference laboratories (WHO based
reference laboratories including CIRMF, Pasteur Institute
Network and other National laboratories or universities
based) and (2) a Health Ecology Observatory (that is,. The
CIRMF’s Scientific Station in la Lope´ National Park). Such
measures will compile data from the public health system
with the monitoring of the emergence of new pathogens.
The collected information would favor better outbreak risk
appraisal in the Gabonese human population as well as for
the entire Congo basin region.
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